192 related articles for article (PubMed ID: 33576169)
21. Head-to-head comparison of PI-RADS v2 and PI-RADS v1.
Polanec S; Helbich TH; Bickel H; Pinker-Domenig K; Georg D; Shariat SF; Aulitzky W; Susani M; Baltzer PA
Eur J Radiol; 2016 Jun; 85(6):1125-31. PubMed ID: 27161062
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic Performance of PI-RADS v2, Proposed Adjusted PI-RADS v2 and Biparametric Magnetic Resonance Imaging for Prostate Cancer Detection: A Preliminary Study.
Cai GH; Yang QH; Chen WB; Liu QY; Zeng YR; Zeng YJ
Curr Oncol; 2021 May; 28(3):1823-1834. PubMed ID: 34065851
[TBL] [Abstract][Full Text] [Related]
23. The Diagnostic Value of PI-RADS v2.1 in Patients with a History of Transurethral Resection of the Prostate (TURP).
Liu J; Pan S; Dong L; Wu G; Wang J; Wang Y; Qian H; Dong B; Pan J; Zhu Y; Xue W
Curr Oncol; 2022 Sep; 29(9):6373-6382. PubMed ID: 36135071
[TBL] [Abstract][Full Text] [Related]
24. Direct comparison of PI-RADS version 2 and version 1 regarding interreader agreement and diagnostic accuracy for the detection of clinically significant prostate cancer.
Becker AS; Cornelius A; Reiner CS; Stocker D; Ulbrich EJ; Barth BK; Mortezavi A; Eberli D; Donati OF
Eur J Radiol; 2017 Sep; 94():58-63. PubMed ID: 28941761
[TBL] [Abstract][Full Text] [Related]
25. Can the addition of clinical information improve the accuracy of PI-RADS version 2 for the diagnosis of clinically significant prostate cancer in positive MRI?
Polanec SH; Bickel H; Wengert GJ; Arnoldner M; Clauser P; Susani M; Shariat SF; Pinker K; Helbich TH; Baltzer PAT
Clin Radiol; 2020 Feb; 75(2):157.e1-157.e7. PubMed ID: 31690449
[TBL] [Abstract][Full Text] [Related]
26. Investigating the role of DCE-MRI, over T2 and DWI, in accurate PI-RADS v2 assessment of clinically significant peripheral zone prostate lesions as defined at radical prostatectomy.
Taghipour M; Ziaei A; Alessandrino F; Hassanzadeh E; Harisinghani M; Vangel M; Tempany CM; Fennessy FM
Abdom Radiol (NY); 2019 Apr; 44(4):1520-1527. PubMed ID: 30361870
[TBL] [Abstract][Full Text] [Related]
27. Assessment of PI-RADS v2 categories ≥ 3 for diagnosis of clinically significant prostate cancer.
Patel NU; Lind KE; Garg K; Crawford D; Werahera PN; Pokharel SS
Abdom Radiol (NY); 2019 Feb; 44(2):705-712. PubMed ID: 30171296
[TBL] [Abstract][Full Text] [Related]
28. Assessment of PI-RADS v2 for the Detection of Prostate Cancer.
Kasel-Seibert M; Lehmann T; Aschenbach R; Guettler FV; Abubrig M; Grimm MO; Teichgraeber U; Franiel T
Eur J Radiol; 2016 Apr; 85(4):726-31. PubMed ID: 26971415
[TBL] [Abstract][Full Text] [Related]
29. Interobserver Agreement and Accuracy in Interpreting mpMRI of the Prostate: a Systematic Review.
Annamalai A; Fustok JN; Beltran-Perez J; Rashad AT; Krane LS; Triche BL
Curr Urol Rep; 2022 Jan; 23(1):1-10. PubMed ID: 35226257
[TBL] [Abstract][Full Text] [Related]
30. Application of Prostate Imaging Reporting and Data System Version 2 (PI-RADS v2): Interobserver Agreement and Positive Predictive Value for Localization of Intermediate- and High-Grade Prostate Cancers on Multiparametric Magnetic Resonance Imaging.
Chen F; Cen S; Palmer S
Acad Radiol; 2017 Sep; 24(9):1101-1106. PubMed ID: 28546032
[TBL] [Abstract][Full Text] [Related]
31. How does PI-RADS v2.1 impact patient classification? A head-to-head comparison between PI-RADS v2.0 and v2.1.
Linhares Moreira AS; De Visschere P; Van Praet C; Villeirs G
Acta Radiol; 2021 Jun; 62(6):839-847. PubMed ID: 32702998
[TBL] [Abstract][Full Text] [Related]
32. Proposed Adjustments to PI-RADS Version 2 Decision Rules: Impact on Prostate Cancer Detection.
Rosenkrantz AB; Babb JS; Taneja SS; Ream JM
Radiology; 2017 Apr; 283(1):119-129. PubMed ID: 27783538
[TBL] [Abstract][Full Text] [Related]
33. Comparison of Prostate Imaging and Reporting Data System V2.0 and V2.1 for Evaluation of Transition Zone Lesions: A 5-Reader 202-Patient Analysis.
Kim N; Kim S; Prabhu V; Shanbhogue K; Smereka P; Tong A; Anthopolos R; Taneja SS; Rosenkrantz AB
J Comput Assist Tomogr; 2022 Jul-Aug 01; 46(4):523-529. PubMed ID: 35405714
[TBL] [Abstract][Full Text] [Related]
34. Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions.
Padhani AR; Weinreb J; Rosenkrantz AB; Villeirs G; Turkbey B; Barentsz J
Eur Urol; 2019 Mar; 75(3):385-396. PubMed ID: 29908876
[TBL] [Abstract][Full Text] [Related]
35. Risk Stratification of Prostate Cancer According to PI-RADS® Version 2 Categories: Meta-Analysis for Prospective Studies.
Park KJ; Choi SH; Lee JS; Kim JK; Kim MH; Jeong IG
J Urol; 2020 Dec; 204(6):1141-1149. PubMed ID: 32716687
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic Performance of Prostate Imaging Reporting and Data System Version 2 for Detection of Prostate Cancer: A Systematic Review and Diagnostic Meta-analysis.
Woo S; Suh CH; Kim SY; Cho JY; Kim SH
Eur Urol; 2017 Aug; 72(2):177-188. PubMed ID: 28196723
[TBL] [Abstract][Full Text] [Related]
37. [Differentiation of prostatitis and clinically significant prostate cancer in peripheral zone using the prostate imaging-reporting and data system].
Zhang TH; Hu CH; Chen JX; Xu ZD; Hu YJ; Cai HF; Shen LP
Zhonghua Yi Xue Za Zhi; 2019 Aug; 99(31):2455-2458. PubMed ID: 31434427
[No Abstract] [Full Text] [Related]
38. Prostate Cancer Differentiation and Aggressiveness: Assessment With a Radiomic-Based Model vs. PI-RADS v2.
Chen T; Li M; Gu Y; Zhang Y; Yang S; Wei C; Wu J; Li X; Zhao W; Shen J
J Magn Reson Imaging; 2019 Mar; 49(3):875-884. PubMed ID: 30230108
[TBL] [Abstract][Full Text] [Related]
39. The Prognostic Association of Prostate MRI PI-RADS™ v2 Assessment Category and Risk of Biochemical Recurrence after Definitive Local Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis.
Rajwa P; Mori K; Huebner NA; Martin DT; Sprenkle PC; Weinreb JC; Ploussard G; Pradere B; Shariat SF; Leapman MS
J Urol; 2021 Sep; 206(3):507-516. PubMed ID: 33904755
[TBL] [Abstract][Full Text] [Related]
40. Assessing the validity of Prostate Imaging Reporting and Data System version 2 (PI-RADS v2) scoring system in diagnosis of peripheral zone prostate cancer.
Dola EF; Nakhla OL; Genidi EA
Eur J Radiol Open; 2017; 4():19-26. PubMed ID: 28377946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
